Cargando…

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

Favorable efficacy and safety profiles have been demonstrated for abatacept in patients with rheumatoid arthritis (RA) in randomized controlled trials, but these data require validation during long-term follow-ups in routine clinical practice. This study explored long-term safety and retention rates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westhovens, R., Connolly, S. E., Margaux, J., Vanden Berghe, M., Maertens, M., Van den Berghe, M., Elbez, Y., Chartier, M., Baeke, F., Robert, S., Malaise, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Cohort Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371673/ https://www.ncbi.nlm.nih.gov/pubmed/32556473 http://dx.doi.org/10.1007/s00296-020-04619-z

Ejemplares similares

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study
por: Durez, Patrick, et al.
Publicado: (2022)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
por: Alten, Rieke, et al.
Publicado: (2023)

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
por: Alten, Rieke, et al.
Publicado: (2022)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
por: Genant, H K, et al.
Publicado: (2008)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Prevalence of rheumatoid arthritis among hospital workers in the north of Jordan: Preliminary report of a hospital-based cohort study
por: Alawneh, Khaldoon M., et al.
Publicado: (2020)

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Predictors for response to electronic patient-reported outcomes in routine care in patients with rheumatoid arthritis: a retrospective cohort study
por: Wiegel, Jimmy, et al.
Publicado: (2023)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
por: Bessette, Louis, et al.
Publicado: (2023)

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
por: Emery, Paul, et al.
Publicado: (2023)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy
por: Kunishita, Yosuke, et al.
Publicado: (2023)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
por: Sato, Shuzo, et al.
Publicado: (2021)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
por: Baganz, Lisa, et al.
Publicado: (2017)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept
por: Deidda, Arianna, et al.
Publicado: (2014)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
por: Imberti, Luisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o97lne7po1ebhjqtggunf9ddr1